NovoCure (NVCR) Cash from Investing Activities (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.70% |
| Dec 31, 2025 | 370.81% |
| Sep 30, 2025 | 98.51% |
| Jun 30, 2025 | 656.03% |
| Mar 31, 2025 | 70.86% |
| Dec 31, 2024 | -317.90% |
| Sep 30, 2024 | 102.72% |
| Jun 30, 2024 | -252.08% |
| Mar 31, 2024 | 149.97% |
| Dec 31, 2023 | 470.75% |
| Sep 30, 2023 | 224.19% |
| Jun 30, 2023 | -116.89% |
| Mar 31, 2023 | 164.26% |
| Dec 31, 2022 | 14.77% |
| Sep 30, 2022 | -196.46% |
| Jun 30, 2022 | 994.64% |
| Mar 31, 2022 | 96.51% |
| Dec 31, 2021 | -264.88% |
| Sep 30, 2021 | 11,662.38% |
| Jun 30, 2021 | -104.83% |
| Mar 31, 2021 | 108.83% |
| Dec 31, 2020 | -516.82% |
| Sep 30, 2020 | 4,540.97% |
| Jun 30, 2020 | -6.52% |
| Mar 31, 2020 | 93.34% |
| Dec 31, 2019 | -2,050.69% |
| Sep 30, 2019 | -24.37% |
| Jun 30, 2019 | -76.74% |
| Mar 31, 2019 | 44.72% |
| Dec 31, 2018 | -78.01% |
| Sep 30, 2018 | -19.36% |
| Jun 30, 2018 | 54.66% |
| Mar 31, 2018 | 4.57% |
| Dec 31, 2017 | -11.07% |
| Sep 30, 2017 | -198.47% |
| Jun 30, 2017 | -104.55% |
| Mar 31, 2017 | 478.68% |
| Dec 31, 2016 | 22.75% |
| Sep 30, 2016 | 33.37% |
| Jun 30, 2016 | -124.14% |
| Mar 31, 2016 | 121.78% |
| Dec 31, 2015 | -560.58% |
| Sep 30, 2015 | 172.19% |
| Jun 30, 2015 | -278.10% |
| Mar 31, 2015 | 408.36% |